Marek Trněný

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Lorenz Trümper, Anders Österborg et al. · The Lancet Oncology · 2006 · 2.1K citations

Medicine, Oncology, Chemotherapy +11

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson et al. · The Lancet · 2010 · 1.9K citations

Medicine, Oncology, Pharmacotherapy +10

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

Christian Gisselbrecht, Nicolas Mounier, Devinder Gill et al. · Journal of Clinical Oncology · 2010 · 1.6K citations · Full text

Medicine, Oncology, Chemotherapy +13

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

Anas Younes, Armando Santoro, Margaret A. Shipp et al. · The Lancet Oncology · 2016 · 924 citations · Full text

Medicine, Hematology, Oncology +16

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper et al. · The Lancet Oncology · 2011 · 811 citations

Medicine, Oncology, Pharmacotherapy +13